Compare abrdn Income Credit Strategies Fund (ACP) vs Pfizer Inc (PFE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Pfizer Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.23 (market cap $656.21M), while Pfizer Inc trades at $24.09 (market cap $137.19B). The key difference: Pfizer Inc is far larger — about 209.1× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | PFE | |
|---|---|---|
Market Cap | $656.21M | $137.19B |
Sector | Financials | Health |
52-Week High | $5.98 | $28.56 |
52-Week Low | $5.01 | $23.29 |
Dividend Yield | 17.78% | 7.15% |
Volume | — | 29,869,932 |
Enterprise Value | — | $187.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Pfizer (PFE) trades at $24.04, up 1.35% on the day, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 18.37 and net margin of 11.83%, supported by strong cash flow from operations of $11.70B in 2025. Recent news highlights pipeline developments in oncology and obesity treatments, positioning for future growth amid patent cliff challenges.
The outlook balances a discounted valuation against near-term revenue pressures. Opportunities include a rich product pipeline and sustainable dividend yield, while risks involve patent expirations and competitive threats. Analyst consensus leans neutral with a $27.63 price target, suggesting cautious optimism for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
